Interestingly, in a KRAS-driven mouse model of lung adenocarcinoma combinatorial therapy with NVP-BEZ235 and ARRY-142886, a MEK inhibitor resulted in a larger reduction of tumor volume compared with NVP-BEZ235 alone (52). Here, KRAS is linked to lung adenocarcinoma.